Brief: Nicox FY Net Revenue Up At 6.9 Million Euros

Nicox SA

06/03/2020 06:38

March 6 (Reuters) - Nicox SA  NCOX.PA :
    * CASH POSITION OF EUR 28.1 MILLION AS OF DECEMBER 31, 2019
    * NET LOSS OF NICOX GROUP FOR FULL YEAR 2019 WAS EUR 18.9
MILLION
AGAINST EUR 18.4 MILLION IN FULL YEAR 2018
    * AS OF DECEMBER 31, 2019, NICOX GROUP HAD A FINANCIAL DEBT
OF EUR
11.1 MILLION IN FORM OF A BOND FINANCING AGREEMENT WITH KREOS
CAPITAL
    * NET REVENUE FOR THE FULL YEAR 2019 WAS €6.9 MILLION ,
COMPARED
TO €4.0 MILLION FOR THE FULL YEAR 2018.
    * AS OF DEC 31, 2019, NICOX GROUP HAD FINANCIAL DEBT OF EUR
11.1
MILLION IN FORM OF BOND FINANCING AGREEMENT WITH KREOS CAPITAL
SIGNED IN JAN 2019 ADJUSTED TO ABOUT EUR 18.8 MILLION BY
INCLUDING LAST TRANCHE OF LOAN DRAWN DOWN IN DEC 2019
    * OPERATING EXPENSES FOR THE PERIOD 2019 DECREASED TO €25.5
MILLION FROM €26.5 MILLION FOR THE 12 MONTHS TO DECEMBER 31,
2018
    * NCX 470 PHASE 3 CLINICAL TRIAL PREPARATION: PHASE 3
CLINICAL
TRIAL (‘MONT BLANC’) IS EXPECTED TO BE INITIATED BY THE END OF
Q2 2020
    * NCX 4251: MEETING WITH THE U.S. FDA IS SCHEDULED IN Q1
2020 TO
DISCUSS THE NEXT STEPS OF THE CLINICAL DEVELOPMENT PLAN
    * ZERVIATEPTMP U.S. LAUNCH: COMMERCIAL LAUNCH OF
ZERVIATEPTMP
(CETIRIZINE OPHTHALMIC SOLUTION), 0.24% IN U.S. IS PLANNED BY
NICOX'S PARTNER EYEVANCE PHARMACEUTICALS IN H1 2020

Source text for Eikon:  ID:nGNE2Xzy6w 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))